Zhang Jiexiang, Yuan Weichen, Zhang Tongtong, Liu Xuesong, Xu Dongliang
Urology Centre, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Surgical Institute of Integrative Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Discov Oncol. 2025 Jul 30;16(1):1441. doi: 10.1007/s12672-025-03304-6.
The androgen receptor (AR) remains a focal target in castration-resistant prostate cancer (CRPC) research, with recent studies providing valuable insights for advancing AR-targeted therapies. This study employs bibliometric methods to comprehensively analyze research trends in the CRPC and AR fields, identifying emerging hotspots and future directions.
Publications from 2005 to 2024 were extracted from the Web of Science Core Collection (WoSCC). Bibliometric analysis and data visualization were performed using VOSviewer, CiteSpace, and the R package "Bibliometrix."
A total of 3,149 publications authored by 15,704 researchers across 75 countries were analyzed. Publication output exhibited rapid growth over the past two decades. The United States dominated contributions, with the University of Washington ranking as the leading institution. Antonarakis, Emmanuel S. was the most prolific author, while Scher, Howard I. emerged as the most cited researcher. PROSTATE published the highest number of studies, whereas CANCER RESEARCH was the most cited journal. References co-citation analysis and keyword burst revealed persistent research emphasis on AR splice variants and CRPC drug resistance, with emerging investigations into novel membrane antigens representing current frontiers.
This study delineates the evolving knowledge framework and shifting priorities in CRPC and AR research, offering strategic insights to guide future AR-targeted therapeutic development for CRPC.
雄激素受体（AR）仍是去势抵抗性前列腺癌（CRPC）研究的重点靶点，近期研究为推进AR靶向治疗提供了有价值的见解。本研究采用文献计量学方法全面分析CRPC和AR领域的研究趋势，确定新兴热点和未来方向。
从科学网核心合集（WoSCC）中提取2005年至2024年的出版物。使用VOSviewer、CiteSpace和R包“Bibliometrix”进行文献计量分析和数据可视化。
共分析了来自75个国家的15704名研究人员撰写的3149篇出版物。在过去二十年中，出版物数量呈现快速增长。美国贡献最大，华盛顿大学是领先机构。埃马努埃尔·S·安托纳拉基斯是发文量最多的作者，而霍华德·I·舍尔是被引频次最高的研究人员。《前列腺》发表的研究数量最多，而《癌症研究》是被引频次最高的期刊。参考文献共被引分析和关键词突现显示，研究持续关注AR剪接变体和CRPC耐药性，对新型膜抗原的新兴研究代表了当前前沿。
本研究描绘了CRPC和AR研究中不断演变的知识框架和优先事项的变化，为指导未来CRPC的AR靶向治疗发展提供了战略见解。
